This article is based on the presentation “Recent Global Updates in Pharmacovigilance Regulations,” delivered by Stella Xu, Senior Director of Pharmacovigilance Operations at Caidya, during the 2026 DIA China Annual Meeting.
The global pharmacovigilance (PV) landscape continues to evolve rapidly. Recent regulatory updates across ICH regions and global health authorities point to a greater emphasis on data quality, transparency, real-world evidence (RWE), AI/ML governance, and risk-based oversight.
During the 2026 DIA China Annual Meeting, Stella Xu, Senior Director of Pharmacovigilance Operations at Caidya, shared an overview of recent PV regulatory developments across CIOMS, ICH, China, the United States, and Europe, highlighting how organizations can better prepare for a more interconnected and increasingly complex regulatory environment.
AI and Digital Transformation Are Reshaping Pharmacovigilance
One of the most notable trends discussed was the growing role of artificial intelligence (AI) and machine learning (ML) in pharmacovigilance.
The CIOMS XIV report, Artificial Intelligence in Pharmacovigilance, reflects increasing industry attention to governance, transparency, human oversight, data privacy, and risk-based implementation of AI technologies in pharmacovigilance. Rather than viewing AI solely as an automation tool, discussions are increasingly focused on how organizations validate, govern, and oversee AI-supported processes.
At the same time, electronic reporting expectations continue to expand. Updates to ICH E2D(R1) and E2B(R3) recognize broader safety data sources, including digital platforms and patient support programs, while also strengthening structured electronic reporting requirements.
Together, these developments demonstrate that digital transformation is becoming increasingly important in PV, while also requiring robust compliance and oversight frameworks.
Real-World Evidence Continues to Gain Momentum
Another major trend is the increasing use of real-world data (RWD) and real-world evidence (RWE) in safety assessment.
ICH M14 introduces recommendations for planning, designing, analyzing, and reporting non-interventional studies using RWD for post-marketing safety evaluation. CIOMS XV also reflects growing attention to the role of pharmacoepidemiology in public health decision-making.
China has also continued expanding its adoption of RWE in regulatory practice. Recent NMPA and CDE guidance documents demonstrate an increasing focus on RWE-based safety assessment, global MRCT benefit-risk evaluation, and patient-centered clinical development approaches.
As regulators place greater value on real-world safety insights, organizations will need stronger data integration capabilities and closer collaboration across safety, clinical, epidemiology, and data science teams.
China’s PV Regulatory Environment Continues to Accelerate
China’s regulatory system has seen significant activity over the past two years, particularly in areas related to clinical safety management, risk management planning, and global harmonization.
Several important developments highlighted during the presentation include:
- Full adoption of ICH E6(R3)
- Accelerated IND review for innovative drugs
- Expanded requirements for Development Risk Management Plans (DRMPs) for innovative drugs
- Updated conditional approval procedures for early access
- Continued development of medical device vigilance regulations
- Expanded use of real-world evidence (RWE) data
These updates reflect China’s continued alignment with international guidance while also strengthening local requirements for safety governance and operational readiness.
EMA Strengthens Oversight of Outsourced PV Activities
In Europe, recent EMA and EU GVP updates reflect a stronger focus on oversight, accountability, and risk-based monitoring.
New requirements place greater responsibility on marketing authorization holders (MAHs) to oversee outsourced PV activities, conduct risk-based audits, and maintain transparency across safety systems and third-party partnerships.
Additional updates also address:
- Enhanced EudraVigilance monitoring
- Data masking and personal data protection in ICSRs
- Signal management simplification
- Post-authorization safety study transparency
- Risk minimization measures
- Expanded audit expectations
These changes reinforce the importance of maintaining robust PV governance models, particularly for organizations operating with global vendors, CROs, and distributed safety operations.
The Future of Pharmacovigilance Requires Cross-Functional Agility
As highlighted throughout the session, the global PV landscape is becoming both more connected and more demanding.
While harmonization efforts continue through organizations such as ICH and CIOMS, regional requirements remain diverse and continue to evolve rapidly. Organizations must therefore remain agile while balancing innovation, compliance, operational efficiency, and data integrity.
Looking ahead, PV organizations will increasingly need:
- Cross-functional collaboration
- Continuous regulatory monitoring
- Strong compliance systems
- AI governance capabilities
- High-quality, interoperable data
- Flexible global operating models
Ultimately, the future of pharmacovigilance will depend not only on technological advancement but also on how effectively organizations combine scientific rigor, operational excellence, and adaptive regulatory strategies in an increasingly complex global environment.